글로벌 혈관신생 억제제 시장 – 2029년까지의 산업 동향 및 예측

글로벌 혈관신생 억제제 시장 분석 및 통찰력

다양한 유형의 암이 많은 사람들에게 영향을 미치는 높은 유병률은 혈관신생 억제제 시장이 예측 기간 내에 엄청난 성장을 경험하는 데 도움이 될 것으로 예상됩니다. 게다가 시장은 COVID-19의 갑작스러운 발병으로 인한 제한의 영향으로 예측 기간 내에 마이너스 성장을 보일 것으로 예상됩니다.

• Data Bridge Market Research는 혈관신생 억제제 시장이 2022년부터 2029년까지의 예측 기간 동안 9.20%의 CAGR로 성장할 것으로 분석했습니다. "VEGF 표적 요법"은 예측 기간 동안 혈관신생 억제제 시장의 제품 세그먼트를 차지합니다.

글로벌 혈관신생 억제제 시장 정의

새로운 혈관의 형성은 혈관신생으로 알려져 있습니다. 혈관신생 억제제라고도 하는 항혈관신생제는 혈관신생 과정을 차단하는 물질입니다. 이러한 약물은 특정 암 치료에 필수적입니다. 혈관신생 억제제는 종양 세포의 성장을 막는 것이 아니라 종양 성장을 지원하는 혈관의 성장을 막는다는 점에서 다른 항암제와 다릅니다.

혈관신생 억제제 시장 동향

운전자

• 증가하는 암 사례 

유방암 , 전립선암, 폐암 등 암에 대한 부담이 전 세계적으로 증가함에 따라 치료 시장 성장률도 확대될 것으로 예상됩니다.

게다가, 연구 개발 투자는 새로운 치료법을 창출하고 시장 성장을 뒷받침하는 성장 결정 요인이기도 합니다. 또한, 치료 옵션의 가용성과 잠재적인 약물로 이어지는 강력한 파이프라인은 혈관신생 억제제 시장의 성장을 더욱 강화할 것입니다.

또한, 의료 기술의 발전과 화학 요법의 부작용 증가는 혈관신생 억제제 시장을 확대할 암입니다. 효과적인 치료 절차에 대한 수요 증가와 같은 다른 요인은 혈관신생 억제제 시장의 성장률에 긍정적인 영향을 미칠 것입니다.

기회

게다가, 암 인식을 높이기 위한 정부 이니셔티브는 시장 성장률에 새로운 기회를 촉진할 것입니다. 또한, 헬스케어 기술의 발전은 미래에 혈관신생 억제제 시장의 성장률을 확대할 것입니다.

제약/도전 과제 글로벌 혈관신생 억제제 시장

However, the high cost of the inhibitor will impede the growth rate of angiogenesis inhibitors market. Additionally, the stringent government regulations hampers the market growth.

This angiogenesis inhibitors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on angiogenesis inhibitors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Angiogenesis inhibitors, are substances that block the process of angiogenesis.  The annual cancer cases are expected rise from14 million to 22 million in next two decades.

Angiogenesis inhibitors market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Angiogenesis Inhibitors Market

The senior population with underlying severe therapeutic conditions, including people with cancer along with the patients with hepatocellular carcinoma might be at higher risk for severe illness from COVID-19 thus influencing market at a high level. Pharmaceutical industries were heavily impacted by the COVID-19. The angiogenesis inhibitors market was however affected negatively by the sudden emergence of the COVID-19, due to suspended of various operations which are not emergency cases as a result of several government restrictions. Moreover, the disruption in supply chain causing delays in the import and export of drugs and medicines for the angiogenesis inhibitors also further creates hurdles for the expansion of the market.

Recent Developments

• In June 2020, Targovax, a biotechnology company, has teamed up with Leidos' Explorations in Global Health (ExGloH) division to see if ONCOS, a Targovax clinical programme of oncolytic adenoviruses, can be used as a vector to encode MicrotideT checkpoint inhibitor peptides. MicrotideTM is a proprietary portfolio of microbially-derived peptides that act as immune checkpoint inhibitors developed by Leidos' Explorations in Global Health (ExGloH) division. Leidos is a defence, aviation, information technology, and biomedical research company based in the United States.

Global Angiogenesis Inhibitors Market Scope

The angiogenesis inhibitors market is segmented on the basis of product, indication, drugs, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• VEGF Targeted Therapy
• FGF Targeted Therapies
• Oncogene Targeted Therapy
• Matrix Degrading and Remodeling Targeted Therapy
• Others

On the basis of product, angiogenesis inhibitors market is segmented into VEGF targeted therapy, FGF targeted therapies, oncogene targeted therapy, matrix degrading and remodeling targeted therapy and others. VEGF targeted therapy segment is expected to grow at the fastest CAGR during the forecast period.

Indication

• Glioblastoma
• Colorectal Cancer
• Others

On the basis of indication, angiogenesis inhibitors market is segmented into glioblastoma, colorectal cancer and others.

Route of Administration

• Oral
• Parenteral
• Others

On the basis of route of administration, the angiogenesis inhibitors market is segmented into oral, parenteral and others.

End-Users

• Hospitals
• Specialty Clinics
• Others

On the basis of end-users, the angiogenesis inhibitors market is segmented into hospitals, specialty clinics and others.

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

On the basis of distribution channel, the angiogenesis inhibitors market is segmented into hospital pharmacy, retail pharmacy and others.

Angiogenesis Inhibitors Market Regional Analysis/Insights

The angiogenesis inhibitors market is analyzed and market size insights and trends are provided by country, product, indication, drugs, route of administration, end-users and distribution channel as referenced above.

The countries covered in the angiogenesis inhibitors market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the angiogenesis inhibitors market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing incidence of cancer in the country, the presence of key market players, and the launch of new commodities influence market growth in this region. Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period due to the factors such as the surging awareness about early diagnosis, growth in healthcare expenditure, high unmet clinical needs of patients as well as the effective treatment in emerging countries such as China and India in the region.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Angiogenesis Inhibitors Market Share Analysis

The angiogenesis inhibitors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to angiogenesis inhibitors market.

Some of the major players operating in the angiogenesis inhibitors market are F. Hoffmann-La Roche Ltd, Pfizer Inc., Exelixis, Inc, Novartis AG, Takeda Pharmaceutical Company Limited, Melinta Therapeutics LLC, Cipla Inc., Sun Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Balaji Medical Services Private Limited,  Eli Lilly and Company,  Bayer AG, Sanofi and Merck & Co., among others.

Research Methodology : Global Angiogenesis Inhibitors Market

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석 및 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭 다운하세요. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 이 외에도 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다 . 연구 방법론에 대해 자세히 알아보려면 문의 사항을 드롭하여 업계 전문가에게 문의하세요  https://www.databridgemarketresearch.com/ko/speak-to-analyst/?dbmr=global-angiogenesis-inhibitors-market

SKU-52558